"Our Antibody Is Better Than Theirs"
Mark Brunswick, senior vice president of regulatory affairs at Sorrento, claims that the company's antibodies are better than the ones being developed by Eli Lilly (NYSE:LLY) and Regeneron (NASDAQ:REGN). Henry Ji, chairman, president, and CEO of Sorrento, explains how the company engineered the antibodies to remove the likelihood of antibody-dependent enhancement (ADE), a phenomenon in which the antibody binding to the virus enhances the entry of the virus into the cell.
Brian Orelli: Antibodies that can bind directly to the coronavirus and block the ability of the virus to infect other cells. We'll start with the STI-1499 which is called COVI-GUARD. It's in a phase 1 study in 33 patients. What's the time frame for having data from that study?
Mark Brunswick: That, we anticipate roughly the same timeline [by the end of January].
Brian Orelli: Your competitor's neutralizing antibodies appear to work best in patients that are in early stage. You're testing patients that are already in the hospital. Are you concerned about that?
Mark Brunswick: No.
Brian Orelli: Why not?
Mark Brunswick: Because we think our antibody is better than theirs. Also, it was a requirement of the FDA initially to go into sicker patients rather than the less sick patients.
Henry Ji: The other thing is if you look at it, Brian, the issue is other neutralizing antibody, when they get the patient in the hospital settings [...] they have safety issues. We engineered very carefully to get rid of the antibody-dependent enhancement which our antibody, 1499 2020 -- all engineered. That means we're going to be avoiding the ADE. So that potentially could be a differentiating factors, our antibody from other antibody.
